These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 28582207)

  • 21. Outcomes of patients with prior coronary artery bypass grafting and acute coronary syndromes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
    Nikolsky E; McLaurin BT; Cox DA; Manoukian SV; Xu K; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2012 Sep; 5(9):919-26. PubMed ID: 22995879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of prerandomization anticoagulant switching with bleeding in the setting of percutaneous coronary intervention (A REPLACE-2 analysis).
    Gibson CM; Ten Y; Murphy SA; Ciaglo LN; Southard MC; Lincoff AM; Waksman R
    Am J Cardiol; 2007 Jun; 99(12):1687-90. PubMed ID: 17560876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study.
    Ferguson JJ; Antman EM; Bates ER; Cohen M; Every NR; Harrington RA; Pepine CJ; Theroux P;
    Am Heart J; 2003 Oct; 146(4):628-34. PubMed ID: 14564315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.
    Saltzman AJ; Stone GW; Claessen BE; Narula A; Leon-Reyes S; Weisz G; Brodie B; Witzenbichler B; Guagliumi G; Kornowski R; Dudek D; Metzger DC; Lansky AJ; Nikolsky E; Dangas GD; Mehran R
    JACC Cardiovasc Interv; 2011 Sep; 4(9):1011-9. PubMed ID: 21939942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should bivalirudin replace heparin during percutaneous coronary interventions?
    Antman EM
    JAMA; 2003 Feb; 289(7):903-5. PubMed ID: 12588276
    [No Abstract]   [Full Text] [Related]  

  • 26. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial.
    Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ
    J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving role of glycoprotein IIb/IIIa inhibitors in the setting of percutaneous coronary intervention strategies to minimize bleeding risk and optimize outcomes.
    Hanna EB; Rao SV; Manoukian SV; Saucedo JF
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1209-19. PubMed ID: 21232714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bivalirudin for patients with acute coronary syndromes.
    Stone GW; McLaurin BT; Cox DA; Bertrand ME; Lincoff AM; Moses JW; White HD; Pocock SJ; Ware JH; Feit F; Colombo A; Aylward PE; Cequier AR; Darius H; Desmet W; Ebrahimi R; Hamon M; Rasmussen LH; Rupprecht HJ; Hoekstra J; Mehran R; Ohman EM;
    N Engl J Med; 2006 Nov; 355(21):2203-16. PubMed ID: 17124018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of antithrombotic therapy in nonurgent percutaneous coronary intervention.
    Summers KM; Holdford DA; Crouch MA
    Pharmacotherapy; 2006 May; 26(5):609-18. PubMed ID: 16637790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.
    Mehran R; Nikolsky E; Lansky AJ; Kirtane AJ; Kim YH; Feit F; Manoukian S; Moses JW; Ebrahimi R; Ohman EM; White HD; Pocock SJ; Dangas GD; Stone GW
    JACC Cardiovasc Interv; 2009 Aug; 2(8):748-57. PubMed ID: 19695543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
    Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW;
    JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of platelet aggregation with eptifibatide, bivalirudin, and heparin in patients undergoing percutaneous coronary intervention receiving clopidogrel pretreatment (The PharmacoDynamic Evaluation of Angiomax, Clopidogrel with or without INtegrilin [DEACON] study).
    Saucedo JF; Aude W; Pacheco R; Thorn B; Matin Z; Husain K; Garza L
    Am J Cardiol; 2005 Jun; 95(12):1453-6. PubMed ID: 15950569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
    Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heparin is Not Inferior to Bivalirudin in Percutaneous Coronary Intervention-Focusing on the Effect of Glycoprotein IIb/IIIa Inhibitor Use: A Meta-Analysis.
    Huang FY; Huang BT; Peng Y; Liu W; Zhao ZG; Wang PJ; Zuo ZL; Zhang C; Liao YB; Luo XL; Meng QT; Chen C; Huang KS; Chai H; Li Q; Chen M; Zhu Y
    Angiology; 2015 Oct; 66(9):845-55. PubMed ID: 25635117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Glycoprotein IIb/IIIa Inhibition in Contemporary Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the National Cardiovascular Data Registry.
    Safley DM; Venkitachalam L; Kennedy KF; Cohen DJ
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1574-82. PubMed ID: 26493250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention.
    Verheugt FW; Steinhubl SR; Hamon M; Darius H; Steg PG; Valgimigli M; Marso SP; Rao SV; Gershlick AH; Lincoff AM; Mehran R; Stone GW
    JACC Cardiovasc Interv; 2011 Feb; 4(2):191-7. PubMed ID: 21349458
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry.
    Lopes RD; Peterson ED; Chen AY; Roe MT; Wang TY; Ohman EM; Magid DJ; Ho PM; Wiviott SD; Scirica BM; Alexander KP
    JACC Cardiovasc Interv; 2010 Jun; 3(6):669-77. PubMed ID: 20630461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention.
    Wang TY; Magid DJ; Ting HH; Li S; Alexander KP; Roe MT; Peterson ED
    Am Heart J; 2014 Jun; 167(6):833-9. PubMed ID: 24890532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials.
    Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS
    Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of Bivalirudin versus Bivalirudin plus glycoprotein IIb/IIIa inhibitor versus heparin plus glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes having percutaneous intervention for narrowed saphenous vein aorto-coronary grafts (the ACUITY trial investigators).
    Kumar D; Dangas G; Mehran R; Kirtane A; Bertrand M; Ebrahimi R; Guagliumi G; Brar S; Fahy M; Heller E; Moses J; Stone G
    Am J Cardiol; 2010 Oct; 106(7):941-5. PubMed ID: 20854954
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.